Posted by AGORACOM-JC
at 8:09 AM on Tuesday, January 26th, 2021
Subsidiary, Health Gauge, successfully displayed its proof-of-concept deployment in a study funded by The Bill and Melinda Gates Foundation, further validating its technology.
Health Gauge was invited in 2019 to participate, as the sole technology provider, in a Bill and Melinda Gates Foundation funded initiative with ICDDR , B (the International Centre for Diarrhoeal Disease Research of Bangladesh) on a research project to study ways to reduce pregnancy complications and mortality, by making healthcare more accessible using wearable solutions.
January 20, 2021 – AI/ML Innovations Inc. (CNSX :AIML.CN ) (OTC:FIRZF) , a company focused on acquiring and furthering Artificial Intelligence/Machine Learning technologies that address urgent societal needs, announces that its subsidiary, Health Gauge, successfully displayed its proof-of-concept deployment in a study funded by The Bill and Melinda Gates Foundation, further validating its technology. Health Gauge was invited in 2019 to participate, as the sole technology provider, in a Bill and Melinda Gates Foundation funded initiative with ICDDR , B (the International Centre for Diarrhoeal Disease Research of Bangladesh) on a research project to study ways to reduce pregnancy complications and mortality, by making healthcare more accessible using wearable solutions. Health Gauge was invited to participate in this study as a result of ICDDR,B’s learning of Health Gauge’s break-through solution in digital pulse and ECG analysis, using simple, affordable, and quality digital signal capture. For this study, Health Gauge’s personal health monitoring solution, including its wearable device, smart phone app, and AI-driven cloud processing platform was used, in conjunction with the support of community-based health service providers.
Conclusion
Studies such as this validate the proof-of-concept of Health Gauge’s products, and show the vast and varied commercial opportunities available within Health Gauge’s bespoke business model. It speaks to the merits and importance of how Health Gauge’s latest generation solutions can help solve important community health problems, in affordable ways, while readily fitting into existing managed care programs – anywhere. Physicians, other healthcare professionals, and individuals can apply and adapt the Health Gauge solution to a number of different health conditions and settings for personal health monitoring and management – showing the larger value of Health Gauge’s device and applications.
Blood pressure related pregnancy maladies are of concern globally, and a leading cause of death amongst pregnant women. Health Gauge’s products have both the ability and opportunity to capitalize on this critical women’s health issue, while providing an invaluable service that has a direct impact on health outcomes.
Background
The study, which commenced in 2019, focused on serving pregnant women who were at risk of developing eclampsia, a hypertension-related significant health risk. Hypertensive disorders of pregnancy (HDP) are extremely dangerous to both the mother and child, and are in fact one of the three leading causes of maternal death worldwide. While hypertension complicates 10% of all pregnancies and is responsible for 14% for all maternal deaths globally, in the developing world it is of even greater concern where mortality rates can be as high as 20%.
Posted by AGORACOM-JC
at 9:31 AM on Monday, January 25th, 2021
The two-day event will feature presentations by eminent psychedelics companies and industry leaders
Novamind CEO and Director Yaron Conforti will present on Wednesday, January 27th at 9:55 AM EST
TORONTO, ON / January 25, 2021 / Novamind Inc. (CSE:NM) (“Novamind” or the “Company”), a mental health company specialized in psychedelic medicine, today announced the Company’s participation at the Psychedelics Investor Conference, hosted by KCSA Strategic Communications on Tuesday, January 26th and Wednesday, January 27th from 9:00 AM – 12:30 PM EST.
The two-day event will feature presentations by eminent psychedelics companies and industry leaders. Novamind CEO and Director Yaron Conforti will present on Wednesday, January 27th at 9:55 AM EST.
“We look forward to connecting with industry leaders and investors to discuss Novamind’s operating model for clinical care and clinical research in psychedelic medicine,” said Conforti.
Posted by AGORACOM-JC
at 8:50 AM on Monday, January 25th, 2021
General (Retired) Rick Hillier will lead KWESST’s new International Advisory Council, which will provide guidance to the Company on its strategic build-out on a global scale.
General Hillier served as Canada’s Chief of Defence Staff (“CDS”) CDS from February 4, 2005, to July 1, 2008.
He is noted for “getting stuff done” and was instrumental in securing additional funding and modernized equipment for the Canadian military in support of Canada’s mission in Afghanistan.
In November 2020, Ontario Premier Doug Ford appointed General Hillier to oversee the province’s vaccination task-force in response to the COVID-19 pandemic.
Ottawa, Ontario–(January 25, 2021) – KWESST Micro Systems Inc. (TSXV: KWE) (“KWESST” or “the Company”) today announced that Canadian General (Retired) Rick Hillier will lead KWESST’s new International Advisory Council, which will provide guidance to the Company on its strategic build-out on a global scale.
General Hillier served as Canada’s Chief of Defence Staff (“CDS”) CDS from February 4, 2005, to July 1, 2008. He is noted for “getting stuff done” and was instrumental in securing additional funding and modernized equipment for the Canadian military in support of Canada’s mission in Afghanistan. In November 2020, Ontario Premier Doug Ford appointed General Hillier to oversee the province’s vaccination task-force in response to the COVID-19 pandemic.
KWESST Executive Chairman, David Luxton, commented that, “We are delighted and honoured that General Hillier, one of Canada’s most revered and universally respected Chiefs of Defence Staffs, has accepted this lead advisory role at KWESST, and we look forward to his wise counsel.”
Posted by AGORACOM-JC
at 7:49 AM on Monday, January 25th, 2021
Announced a partnership agreement with BOOK YOUR STADIUM ( www.bookyourstadium.com ) to deliver ‘one-of-a-kind’ AR experiences from historical soccer clubs in LaLiga ( Spain ) to fans around the world.
The clubs which BOOK YOUR STADIUM is currently offering in the platform are REAL MADRIDCF , REAL SOCIEDAD CF , REAL VALLADOLID CF, VALENCIA CF, ATHLETIC CLUB , CA OSASUNA , REAL BETIS BALOMPIÉ, and RC CELTA .
Throughout 2021, several national and international clubs are expected to join the platform.
VANCOUVER, BC and ERIE, Pa. , Jan. 25, 2020 – ImagineAR (IP:CSE) (IPNFF:OTCQB) an Augmented Reality company that enables sports teams, entertainers, brands and businesses to instantly create immersive global mobile phone AR campaigns, is excited to announce a partnership agreement with BOOK YOUR STADIUM ( www.bookyourstadium.com ) to deliver ‘one-of-a-kind’ AR experiences from historical soccer clubs in LaLiga ( Spain ) to fans around the world. The clubs which BOOK YOUR STADIUM is currently offering in the platform are REAL MADRIDCF , REAL SOCIEDAD CF , REAL VALLADOLID CF, VALENCIA CF, ATHLETIC CLUB , CA OSASUNA , REAL BETIS BALOMPIÉ, and RC CELTA . Throughout 2021, several national and international clubs are expected to join the platform.
Joaquín Martínez, CEO of BOOK YOUR STADIUM , states: ” We have developed a revolutionary online e-commerce fan engagement site and incorporated ‘best of breed’ innovative digital products. ImagineAR is a leader for sports fan AR engagement and we are going to partner on unique fan AR immersive experiences featuring top LaLiga soccer club players. Additionally, we are now an authorized ImagineAR partner to market their SDK platform to LaLiga clubs for integration into their existing mobile apps which are used by tens of millions of fans around the world.”
BOOK YOUR STADIUM ( www.bookyourstadium.com ), currently available in Spanish, is expected to be available in English in February 2021 and expand globally. Initially, soccer fans can choose from over 200 experiences, adapted to the current health restrictions, to select from historical clubs in LaLiga. Some examples of experiences available include: access to virtual match experiences with exclusive content and games, e-sports matches with football players, Immersive AR experiences, virtual autographs, original match day events, or enjoy club lunch at home. In addition, there is the option of the SPORTBOX® , a themed gift box full of surprises with selected experiences from some clubs.
Posted by AGORACOM-JC
at 7:58 AM on Thursday, January 21st, 2021
Announced significant expansion of our KAI Medical Laboratory in Dallas, Texas in anticipation of projected growth in COVID-19 testing requirements in the U.S., Canada and international markets.
In addition, Empower has filed a Medical Device Establishment Licence with Health Canada for the purposes of importing, distributing and selling our KAI Medical COVID-19 Saliva Test, which has experienced immediate success since it’s launch on December 15, 2020 in the United States and reported on January 7, 2021.
VANCOUVER, BC / January 21, 2021 / EMPOWER CLINICS INC. (CSE:CBDT)(OTCQB:EPWCF)(Frankfurt:8EC) (“Empower” or the “Company“) an integrated healthcare company serving patients through clinics, a telemedicine platform, and a leading medical diagnostics laboratory processing thousands of COVID-19 specimens and developing novel COVID-19 testing protocols for CE, FDA EUA and Health Canada approval, is pleased to announce significant expansion of our KAI Medical Laboratory in Dallas, Texas in anticipation of projected growth in COVID-19 testing requirements in the U.S., Canada and international markets.
In addition, Empower has filed a Medical Device Establishment Licence (“MDEL”) with Health Canada for the purposes of importing, distributing and selling our KAI Medical COVID-19 Saliva Test (“KAI Saliva”), which has experienced immediate success since it’s launch on December 15, 2020 in the United States and reported on January 7, 2021.
KAI MEDICAL LABORATORY EXPANDING TO AT LEAST DOUBLE CURRENT SIZE IN ANTICIPATION OF ANTICIPATED GROWTH IN VOLUME
KAI Medical Laboratory, a state-of-the-art diagnostics laboratory in Dallas, was acquired by Empower Clinics on October 6, 2020 to further advance the Company’s COVID-19 national testing programs for enterprise clients, including movie and television studios, businesses and the travel industry. KAI experienced significant growth in its first quarter under Empower, with Q4 COVID-19 test kit volumes exceeding 6,000 units, far surpassing the 1,300 total units prior to acquisition.
Current run rate projections now indicate as follows:
January 2021 is expected to exceed 8,000 tests, surpassing all of Q4 2020
February 2021 could see daily rates hit 1,000 tests per day
March 2021 could see daily rates hit 2,000 tests per day
Empower Clinics CEO, Steven McAuley stated “Our investment in R&D is really starting to pay off for KAI Medical, starting with a new state-of-art laboratory information system to automate processes for the anticipated growth in volume. Next, we have hired three new scientists, increased administrative staff and are activating a call center to provide world-class customer support. Further, the investment in new test protocols such as the Kai Saliva test kit, combined with our Health Canada medical device licence, positions us to be a leader in the reactivation of travel for Canadians.”
Posted by AGORACOM-JC
at 8:42 AM on Wednesday, January 20th, 2021
Company launches first-ever COVID-safe location-based (LBE) Virtual Reality attractions division “UNCONTAINED” to disrupt the marketplace and fulfill demand from its Family Entertainment Center (FEC) clients.
Immersive Tech is planning for a public listing in the first half of 2021.
Leading immersive experience company builds upon current and past relationships with major companies.
Announcement brings creation of the world’s first-ever free-roam interactive VR franchise attraction available for rapid sale to the global attraction and entertainment marketplace.
VANCOUVER, British Columbia, Jan. 20, 2021 — Victory Square Technologies Inc. (“VST”) (CSE:VST) (OTC:VSQTF) (FWB:6F6) , a company that provides investors access to a diverse portfolio of companies in key sectors including: digital health, gaming, blockchain, AR/VR, cybersecurity, and cloud computing, is pleased to announce that its portfolio company Immersive Tech (“Company”) has launched a premiere new Location-Based Entertainment (LBE) VR attractions division named UNCONTAINED to capitalize on the growing demand for COVID-safe attractions. UNCONTAINED will be the world’s first free-roam interactive VR franchise attraction, built for a COVID world within shipping containers. The experience will allow for up to six players to roam freely within the container while interacting inside a digital environment as a team while making decisions that help guide and define the story.
Immersive Tech designs, engineers and builds custom technology-driven experiences, whether they facilitate brand integration or are aiming to create the best real life adventure possible. The Company recently announced the creation of three unique entertainment escape rooms custom designed and built for Apex Entertainment’s new location in Virginia Beach VA, USA. The three custom room themes include an underwater submarine adventure, a post-war bunker experience, and an AI-controlled warship gone rogue featuring a race against time and a family-friendly focus.
“UNCONTAINED” leverages the manner of design experience that Immersive Tech has gained and honed over the past four years in creating and launching highly successful interactive escape rooms for Family Entertainment Centers. This is complemented by a fundamental understanding of shipping containers as highlighted in their recent 3-room escape experience for Leaps by Bayer, a Bayer Pharmaceutical company, in 2020.
Tags: small cap, small cap stocks, stocks, telehealth, telemedicine, tsx Posted in Victory Square Technologies Inc. | Comments Off on Victory Square Technologies $VST.ca $VSQTF Portfolio Company, Immersive Tech, Announces the Creation of World’s First #COVID-safe Location-Based Entertainment (LBE) Virtual Reality #VR Division “UNCONTAINED” $DBO.ca $YDX.ca $SEV.ca $NTAR.ca
Posted by AGORACOM-JC
at 9:19 AM on Tuesday, January 19th, 2021
Hydreight provides a completely compliant turnkey business model for health professionals to offer fully licensed medical, health & wellness services through an on-demand and on-site platform.
In addition to providing telehealth services, Hydreight also provides a diverse suite of health & wellness protocols that include IV drip, Botox, COVID-19 testing, and other medical and medispa treatments.
Hydreight is a USA certified e-script and telemedicine provider, allowing Hydreight to offer a wide array of health and medical services in all 50 states.
Hydreight provides full pharmaceutical offerings across the United States (Hydreight has full 503B Pharmaceutical supply capabilities ).
Hydreight has established key relationships and supply network chains with major vendors including: Medline, Mckesson, Allergan (Botox), Galderma and numerous pharmacies.
VANCOUVER, British Columbia, Jan. 19, 2021 — Victory Square Technologies Inc. (” Victory Square ” or the “ Company ”) (CSE:VST) (OTC:VSQTF) (FWB:6F6), a company that provides investors access to a diverse portfolio of companies in key sectors including: digital health, gaming, blockchain, AR/VR, cybersecurity, and cloud computing, is pleased to announce that it has signed a binding letter of intent (the “ LOI ”) dated January 13, 2021 in respect of the acquisition (the “ Acquisition ”) of all of the shares of IV Hydreight Inc. (“ Hydreight ”), a mobile health and wellness service provider operating in the United States.
Founded in 2018, Hydreight provides a unique, custom built, proprietary telemedicine service that allows users to book confidential health & wellness and/or medical services at their home, hotel, office or wherever they may need discreet assistance. The business model of Hydreight leverages decentralized healthcare to bring quality telehealth, medical, health and wellness services to the masses in an efficient, scalable and cost effective way.
Posted by AGORACOM-JC
at 9:09 AM on Tuesday, January 19th, 2021
Announces Appointment of Dr. Jinyu Mo as Senior Vice President, Asia
Opened a product design and development center in Shenzhen, China, which will be focused on the optical engine, reference designs for customer applications and new product activities.
POET also announced the appointment of Dr. Jinyu Mo as its Senior Vice President of Asia, with responsibility for managing the Company’s activities in China and Singapore. Dr. Mo is a highly experienced technical and business veteran of the photonics and optoelectronics industries.
TORONTO, Jan. 19, 2021 — POET Technologies Inc. (“ POET ” or the “ Company ”) (TSX Venture: PTK; OTCQX: POETF), the designer and developer of the POET Optical Interposer™ and Photonic Integrated Circuits (PICs) for the data center and tele-communication markets, announced today that it has opened a product design and development center in Shenzhen, China, which will be focused on the optical engine, reference designs for customer applications and new product activities.
POET also announced the appointment of Dr. Jinyu Mo as its Senior Vice President of Asia, with responsibility for managing the Company’s activities in China and Singapore. Dr. Mo is a highly experienced technical and business veteran of the photonics and optoelectronics industries. She has over 22 years of experience spanning several companies, including MACOM Technology Solutions, Bookham/Oclaro, Huawei, I2R in Singapore and Nexvave Photonics Technology Co., which she founded and served as Chief Technology Officer. Dr. Mo was most recently with MACOM as the Senior Director and Chief Scientist of the Lightwave business unit in Asia and site leader in Shenzhen. Dr. Mo received her PhD degree in Optical Communications from Nanyang Technological University (NTU) Singapore. She is a Senior member of IEEE and has been a member of IEEE’s Technical Committees for several international conferences.
POET Optoelectronics Shenzhen Co. Ltd., a wholly foreign-owned enterprise (WFOE) and wholly-owned subsidiary of POET, will augment the Company’s existing design, development and engineering operations in Allentown, Pennsylvania and Singapore. The Shenzhen operation will also support the activities of Super Photonics Xiamen Co. Ltd., the Company’s joint venture with Sanan IC, a subsidiary of Sanan Optoelectronics Co., Ltd. (Shanghai Stock Exchange, SSE: 600703).
Posted by AGORACOM-JC
at 8:05 AM on Tuesday, January 19th, 2021
Pierre Bou-Mansour is former COO of LifeLabs, one of Canada’s largest medical service companies
Announced the expansion of its leadership team with the appointment of Pierre Bou-Mansour, P.Eng., to the role of Chief Operating Officer.
Effective immediately, Mr. Bou-Mansour will assume responsibility for ensuring operational excellence as Novamind develops its network of clinics, retreats, and research sites in 2021 and beyond.
Most recently, he served as the Chief Laboratory Operations Officer of Public Health Ontario, serving Canada’s largest province with over 14 million residents.
In this role, Bou-Mansour successfully led the expansion of Public Health Ontario’s testing capacity for the COVID-19 response.
TORONTO, ON / January 19, 2021 / Novamind Inc., (CSE:NM) (“Novamind” or the “Company”) a mental health company specialized in psychedelic medicine, announces the expansion of its leadership team with the appointment of Pierre Bou-Mansour, P.Eng., to the role of Chief Operating Officer. Effective immediately, Mr. Bou-Mansour will assume responsibility for ensuring operational excellence as Novamind develops its network of clinics, retreats, and research sites in 2021 and beyond.
An accomplished senior executive and leader, Pierre brings a wealth of experience managing large and complex healthcare organizations. Most recently, he served as the Chief Laboratory Operations Officer of Public Health Ontario, serving Canada’s largest province with over 14 million residents. In this role, Bou-Mansour successfully led the expansion of Public Health Ontario’s testing capacity for the COVID-19 response.
Pierre Bou-Mansour said, “Novamind’s Cedar Psychiatry clinics and Cedar Clinical Research sites are both well-positioned to scale as regulated access to psychedelic medicine continues to expand rapidly in jurisdictions around the world. I look forward to working with the leadership team to ensure strategic expansion of our operating model for clinical care and clinical research in psychedelic medicine.”
Pierre has a proven track record for growing and transforming healthcare companies. He spent eight years at LifeLabs, serving as the COO from 2017 to 2019, and successfully led the integration of two acquired competitors. During this period, LifeLabs grew into one of the largest medical service companies in Canada, with over 5,700 employees, 370 patient access sites, and over US $977 million in annualized revenue (dnb.com).
Yaon Conforti, Chief Executive Officer and Director of Novamind added, “Pierre brings a distinguished operational track record in healthcare to drive the expansion of Novamind’s network of mental health clinics and clinical research sites. His role is critical as we execute against our pipeline of growth opportunities.”
